ALGO -16.57% QoQ Amid Product Replacements and Market Volatility

On NOV 14 2025, ALGO dropped by 3.16% within 24 hours to reach $0.1622, ALGO dropped by 8.77% within 7 days, dropped by 8.57% within 1 month, and dropped by 51.51% within 1 year.

The Alargo pharmaceutical firm highlighted a key product transition in its Q3 2025 earnings call. Alargo is replacing Akaroid with its third product, NHD (Novo Hélicine Dépôt), which is now authorized for sale. NHD has demonstrated robust performance, with gross sales increasing by nearly 80% year over year, already surpassing Akaroid in revenue. The company attributes this growth to a targeted strategy of working directly with doctors to promote NHD.

Optimization efforts at AXI are also yielding results. While volume has dropped significantly—approximately 60% as of September 25 compared to average Q1 2025 levels—this is due to the intentional delisting of low-margin products beginning in April 2025. The contribution margin per piece has more than doubled in the same period. Additionally, the EBITDA margin at the group level increased by approximately one percentage point as a result of reduced low-margin AXI revenues.

ARCO Pharma is also undergoing a strategic transformation to strengthen its market position. The company is focusing on rebranding, enhancing communication of product advantages, and emphasizing the unique superiority of its manufacturing processes to pharmacists—key decision-makers in the distribution chain. Medical trainers are being employed to educate sales representatives and pharmacists on the scientific merits of ARCO’s offerings.

Analysts project that the continued shift from low-margin products and the focus on core offerings could support long-term margin expansion. However, the short-term decline in volume and the ongoing transformation costs pose challenges to near-term revenue.